Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Genomind is a specialized mental health care company focused on pharmacogenomic testing. In February 2024, Myriad Genetics acquired select assets from Genomind, including its flagship products like the Genecept Assay® and Genomind® Professional PGx Express™. These tools analyze key genes influencing an individual's response to psychiatric medications, providing clinicians with actionable insights for personalized treatment strategies. The goal is to reduce trial-and-error in medication selection, thereby improving patient outcomes. The Genomind brand and its associated tests, now part of Myriad Genetics, continue to serve clinicians and patients, aiming to bridge genetics and mental health with data-driven information.
The King of Prussia facility historically served as the central hub for Genomind's operations, including research and development, CLIA-certified laboratory services, customer support, and corporate administration. These functions related to Genomind products are now part of Myriad Genetics.
The facility is situated in a modern office park, likely equipped with state-of-the-art laboratory facilities for genetic testing and analysis. Its location offers proximity to other life science companies and research institutions.
The work culture historically associated with Genomind likely emphasized innovation, scientific rigor, collaboration, and a patient-centric approach, driven by its mission to improve mental health care. This ethos is expected to carry forward within Myriad Genetics' mental health division.
King of Prussia's location in the Greater Philadelphia area provides access to a rich talent pool in biotechnology, pharmaceuticals, and healthcare, as well as proximity to leading academic and research institutions, fostering innovation and partnerships relevant to pharmacogenomics.
While Genomind's primary physical operations and laboratory were historically based in the United States, its services reached patients and clinicians in the U.S. and Canada. Following the acquisition of its key assets by Myriad Genetics, these products continue to be available in these markets. Myriad Genetics has a broader global presence, which may influence the future reach of Genomind's pharmacogenomic solutions. Genomind's research has also contributed to the global understanding of pharmacogenomics in mental health through publications and educational initiatives.
2200 Renaissance Blvd, Suite 100
King of Prussia
PA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Genomind' leadership includes:
Genomind has been backed by several prominent investors over the years, including:
The most significant event impacting Genomind's executive structure was the acquisition of its key assets by Myriad Genetics in February 2024. Leadership for the Genomind product lines is now integrated within Myriad Genetics. Specific executive movements for the Genomind-branded unit post-acquisition under Myriad are not typically publicized as distinct Genomind announcements.
Discover the tools Genomind uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its asset acquisition by Myriad Genetics, Genomind likely utilized common corporate email formats. A frequently observed pattern for companies of its type is the first initial followed by the last name. Email communications regarding Genomind products and services would now typically originate from Myriad Genetics email domains.
[first_initial][last]@genomind.com
Format
jdoe@genomind.com
Example
80%
Success rate
Myriad Genetics • February 29, 2024
Myriad Genetics announced the completion of its acquisition of key assets from Genomind, Inc., including the Genecept Assay®, Genomind Professional PGx Express™ test, and Genomind Mental Health Map™. This strategic acquisition aims to enhance Myriad's mental health offerings and expand patient access to precision medicine....more
Business Wire • October 4, 2023
Genomind announced a collaboration with Albertsons Companies to make its pharmacogenomic (PGx) testing services more accessible to patients through Albertsons' extensive network of pharmacies. The partnership aimed to empower pharmacists and patients with genetic insights for medication management in mental health....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Genomind, are just a search away.